GlassScriptPhysician profile
Mili Shum
NPI 1407134224
$94,680.44
in general payments reported to CMS, 2019-2025
21 companies · $4,307 in 2025
The $4,307 reported for 2025 was more than what 84% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13K · 2021: $9,921 · 2022: $47K · 2023: $7,594 · 2024: $1,421 · 2025: $4,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,662 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,875 · Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,661.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,875.00 |
| Food and Beverage | $2,785.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73,086.13 | 2019-2025 | Nucala |
| Pfizer INC. | $10,457.86 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $6,377.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,854.57 | 2019-2025 | Tezspire |
| Genzyme Corporation | $1,051.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $323.84 | 2019-2024 | Dupixent |
| Adma Biomanufacturing LLC | $274.09 | 2024 | |
| Shire North American Group INC | $244.99 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $207.01 | 2024-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $187.34 | 2022-2025 | Orladeyo |
| Jazz Pharmaceuticals INC. | $124.55 | 2019 | |
| Blueprint Medicines Corporation | $120.77 | 2023-2024 | Ayvakit |
| Csl Behring | $106.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2025 | Cuvitru |
| Kaleo, INC. | $69.05 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33.51 | 2019 | |
| Grifols USA, LLC | $31.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.00 | 2023 | Proair Digihaler |
| Janssen Biotech, INC. | $18.79 | 2023 | Tremfya |
| Phadia US INC. | $11.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mili Shum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.